Evidence map›Paper›PMID 35755851›Full record

ArticleFrontiers in cellular and infection microbiology2022

Epidemiology, Clinico-Pathological Characteristics, and Comorbidities of SARS-CoV-2-Infected Pakistani Patients.

Saadia Omer, Mehrunnisa Fatima Gondal, Muhammad Usman, Muhammad Bilal Sarwar, Muhammad Roman, Alam Khan, Nadeem Afzal, Tanveer Ahmed Qaiser, Muhammad Yasir, Faheem Shahzad and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Saadia OmerDepartment of Immunology, University of Health Sciences, Lahore, Pakistan.
Mehrunnisa Fatima GondalDepartment of Immunology, University of Health Sciences, Lahore, Pakistan.
Muhammad UsmanAllama Iqbal Medical College, Jinnah Hospital, Lahore, Pakistan.
Muhammad Bilal SarwarDepartment of Immunology, University of Health Sciences, Lahore, Pakistan.
Muhammad RomanDepartment of Immunology, University of Health Sciences, Lahore, Pakistan.
Alam KhanDepartment of Immunology, University of Health Sciences, Lahore, Pakistan.
Nadeem AfzalDepartment of Immunology, University of Health Sciences, Lahore, Pakistan.
Tanveer Ahmed QaiserDepartment of Molecular Biology, Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad, Pakistan.
Muhammad YasirQuadram Institute Bioscience, Norwich Research Park, Norwich, United Kingdom.
Faheem ShahzadDepartment of Immunology, University of Health Sciences, Lahore, Pakistan.
Romeeza TahirDepartment of Immunology, University of Health Sciences, Lahore, Pakistan.
Saima AyubInstitute of Public Health, Health Department, Government of Punjab, Lahore, Pakistan.
Javed AkramDepartment of Immunology, University of Health Sciences, Lahore, Pakistan.
Raja Muhammad FaizanDepartment of Medicine, Shifa College of Medicine, Islamabad, Pakistan.
Muhammad Asif NaveedDepartment of Immunology, University of Health Sciences, Lahore, Pakistan.
Shah JahanDepartment of Immunology, University of Health Sciences, Lahore, Pakistan.
University of Health Sciences Lahore · PKGovernment of Pakistan · PKGovernment of PunjabJinnah Postgraduate Medical Center · PKQuadram Institute · GBShaheed Zulfiqar Ali Bhutto Institute of Science and Technology · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 is a causative agent for COVID-19 disease, initially reported from Wuhan, China. The infected patients experienced mild to severe symptoms, resulting in several fatalities due to a weak understanding of its pathogenesis, which is the same even to date. This cross-sectional study has been designed on 452 symptomatic mild-to-moderate and severe/critical patients to understand the epidemiology and clinical characteristics of COVID-19 patients with their comorbidities and response to treatment. The mean age of the studied patients was 58 ± 14.42 years, and the overall male to female ratio was 61.7 to 38.2%, respectively. In total, 27.3% of the patients had a history of exposure, and 11.9% had a travel history, while for 60% of patients, the source of infection was unknown. The most prevalent signs and symptoms in ICU patients were dry cough, myalgia, shortness of breath, gastrointestinal discomfort, and abnormal chest X-ray (

Indexed as

COVID-19SARS-CoV-2AdultAgedComorbidityCross-Sectional StudiesFemaleHumansMaleMiddle AgedPakistanRetrospective StudiesAcute Respiratory Distress Syndrome (ARDS)clinic-pathological characteristicscomorbiditiesCOVID-19ICU vs. non-ICULungs-CT-scanmedicationSARS-CoV-2

Identifiers

PMID35755851
PMCPMC9226825
OpenAlexW4281691359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.